Clinical trials: sponsored by Eli Lilly and Company
Melanoma, Prostate Cancer
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with…
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- IVY (NCT02009449)
- Testing
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
- Where
- 10 sites in United States
- Volunteers
- 353 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-CVOT (NCT04255433)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 635 sites in United States, Argentina and 29 more
- Volunteers
- 13,299 people
- Sponsor
- Eli Lilly and Company
Obesity, Obese
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
- Conditions
- Obesity, Obese, Overweight or Obesity
- Trial name
- NCT05616013
- Testing
- Bimagrumab, Semaglutide
- Where
- 26 sites in United States, Australia and 1 more
- Volunteers
- 507 people
- Sponsor
- Eli Lilly and Company
Healthy Adult Subjects
A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
To evaluate the pharmacokinetics of different dose levels and dose formulations of pegilodecakin in healthy adult participants.
- Trial name
- Willow 2 (NCT03381547)
- Testing
- Pegilodecakin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
- Conditions
- Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
- Trial name
- CYCLONE 3 (NCT05288166)
- Testing
- Abemaciclib, Abiraterone, Prednisone or Prednisolone
- Where
- 266 sites in United States, Argentina and 22 more
- Volunteers
- 925 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
The purpose of this study is to determine the long-term safety of the study intervention orforglipron as a monotherapy or in combination with oral antihyperglycemic medication.
- Trial name
- ACHIEVE-J (NCT06010004)
- Testing
- Orforglipron
- Where
- 40 sites in Japan
- Volunteers
- 401 people
- Sponsor
- Eli Lilly and Company
Migraine
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17.
- Trial name
- PIONEER-PEDS2 (NCT04396574)
- Testing
- Lasmiditan
- Where
- 134 sites in United States, Belgium and 13 more
- Volunteers
- 558 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.
- Trial name
- RA-BRIDGE (NCT03915964)
- Testing
- Baricitinib, TNF Inhibitor
- Where
- 261 sites in United States, Australia and 22 more
- Volunteers
- 2,659 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or…
- Trial name
- NCT06230523
- Testing
- Eloralintide
- Where
- 43 sites in United States
- Volunteers
- 263 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease, Dementia
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might…
- Conditions
- Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05738486
- Testing
- Donanemab, Dexamethasone
- Where
- 49 sites in United States, United Kingdom
- Volunteers
- 1,175 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease
- Trial name
- NCT05063539
- Testing
- LY3372689
- Where
- 69 sites in United States, Australia and 3 more
- Volunteers
- 327 people
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
- Trial name
- LUCENT-URGE (NCT05767021)
- Testing
- Mirikizumab
- Where
- 120 sites in United States, Belgium and 8 more
- Volunteers
- 172 people
- Sponsor
- Eli Lilly and Company
Renal Insufficiency, Healthy
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.
The main purpose of this study is to assess the amount of study drug (LY3502970) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared…
- Trial name
- NCT05936138
- Testing
- LY3502970
- Where
- 4 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Multiple Dose Study of LY3502970 in Healthy Participants
The main purpose of this study is to assess how fast LY3502970 gets into the blood stream and how long it takes the body to remove it when administered in multiple oral doses as new formulation compared to that of reference…
- Trial name
- NCT05051566
- Testing
- LY3502970, Esomeprazole
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Two Different Formulations of LY3502970 in Healthy Participants
The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream when administered as two different formulations in healthy participants.
- Trial name
- NCT05341089
- Testing
- LY3502970
- Where
- Singapore
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants
The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with clarithromycin in healthy participants.
- Trial name
- NCT05469126
- Testing
- LY3502970, Clarithromycin
- Where
- Singapore
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Hepatic Insufficiency
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to…
- Trial name
- NCT05882032
- Testing
- LY3502970
- Where
- 4 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Phase I Study of LY3502970 in Healthy Participants
The main purpose of this study is to evaluate how much of the study drug (LY3502970) and the radioactive substance 14C incorporated LY3502970 gets into the bloodstream, how its broken down, and how long it takes the body to get…
- Trial name
- NCT06085482
- Testing
- LY3502970, [14C]-LY3502970
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of LY3502970 in Participants With Type 2 Diabetes
The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it.
- Trial name
- NCT04426474
- Testing
- LY3502970
- Where
- 6 sites in United States, Germany
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY3502970 in Healthy Male Participants
The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to eliminate it. This study will involve a single dose of ¹⁴C radiolabelled LY3502970.
- Trial name
- NCT04680767
- Testing
- [¹⁴C]-LY3502970
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company